Cutaneous mucormycosis by Rhizopus arrhizus treated with isavuconazole as first line therapy: A case report

Mucormycosis are a group of infections that affect principally immunocompromised host and have a high mortality. Liposomal amphotericin B is the first-line treatment with combined surgical removal of the infectious focus. We report the case of 67-year-old man with idiopathic granulocytic aplasia and...

Descripción completa

Detalles Bibliográficos
Autores principales: Zuglian, G., Ripamonti, D., Tebaldi, A., Rizzi, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6812037/
https://www.ncbi.nlm.nih.gov/pubmed/31667060
http://dx.doi.org/10.1016/j.mmcr.2019.10.002
_version_ 1783462590600445952
author Zuglian, G.
Ripamonti, D.
Tebaldi, A.
Rizzi, M.
author_facet Zuglian, G.
Ripamonti, D.
Tebaldi, A.
Rizzi, M.
author_sort Zuglian, G.
collection PubMed
description Mucormycosis are a group of infections that affect principally immunocompromised host and have a high mortality. Liposomal amphotericin B is the first-line treatment with combined surgical removal of the infectious focus. We report the case of 67-year-old man with idiopathic granulocytic aplasia and a cutaneous lesion caused by Rhizopus arrhizus treated with isavuconazole. Its safety profile and spectrum of activity make it an important therapeutic option.
format Online
Article
Text
id pubmed-6812037
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-68120372019-10-30 Cutaneous mucormycosis by Rhizopus arrhizus treated with isavuconazole as first line therapy: A case report Zuglian, G. Ripamonti, D. Tebaldi, A. Rizzi, M. Med Mycol Case Rep Case Report Mucormycosis are a group of infections that affect principally immunocompromised host and have a high mortality. Liposomal amphotericin B is the first-line treatment with combined surgical removal of the infectious focus. We report the case of 67-year-old man with idiopathic granulocytic aplasia and a cutaneous lesion caused by Rhizopus arrhizus treated with isavuconazole. Its safety profile and spectrum of activity make it an important therapeutic option. Elsevier 2019-10-03 /pmc/articles/PMC6812037/ /pubmed/31667060 http://dx.doi.org/10.1016/j.mmcr.2019.10.002 Text en © 2019 Published by Elsevier B.V. on behalf of International Society for Human and Animal Mycology. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Zuglian, G.
Ripamonti, D.
Tebaldi, A.
Rizzi, M.
Cutaneous mucormycosis by Rhizopus arrhizus treated with isavuconazole as first line therapy: A case report
title Cutaneous mucormycosis by Rhizopus arrhizus treated with isavuconazole as first line therapy: A case report
title_full Cutaneous mucormycosis by Rhizopus arrhizus treated with isavuconazole as first line therapy: A case report
title_fullStr Cutaneous mucormycosis by Rhizopus arrhizus treated with isavuconazole as first line therapy: A case report
title_full_unstemmed Cutaneous mucormycosis by Rhizopus arrhizus treated with isavuconazole as first line therapy: A case report
title_short Cutaneous mucormycosis by Rhizopus arrhizus treated with isavuconazole as first line therapy: A case report
title_sort cutaneous mucormycosis by rhizopus arrhizus treated with isavuconazole as first line therapy: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6812037/
https://www.ncbi.nlm.nih.gov/pubmed/31667060
http://dx.doi.org/10.1016/j.mmcr.2019.10.002
work_keys_str_mv AT zugliang cutaneousmucormycosisbyrhizopusarrhizustreatedwithisavuconazoleasfirstlinetherapyacasereport
AT ripamontid cutaneousmucormycosisbyrhizopusarrhizustreatedwithisavuconazoleasfirstlinetherapyacasereport
AT tebaldia cutaneousmucormycosisbyrhizopusarrhizustreatedwithisavuconazoleasfirstlinetherapyacasereport
AT rizzim cutaneousmucormycosisbyrhizopusarrhizustreatedwithisavuconazoleasfirstlinetherapyacasereport

Ejemplares similares